Cancer Biotherapy and Radiopharmaceuticals, Journal Year: 2025, Volume and Issue: unknown
Published: May 21, 2025
Introduction: Pancreatic cancer remains one of the most challenging malignancies to treat, characterized by limited therapeutic options and persistently poor survival rates. Conventional radiotherapy presents several limitations, including nonspecific tumor targeting, elevated toxicity adjacent healthy tissues, intrinsic radioresistant pancreatic tumors, necessitating innovative treatment strategies. In comparison previous studies, which reported a median rate 12 months for patients undergoing conventional radiotherapy, results this study demonstrate significant improvement, with increase 18 using novel targeted approach. Additionally, our findings show 30% reduction in off-target tissue toxicity, compared 45% seen traditional methods. Methods: Nanoparticle-enhanced (NERT) introduces approach biocompatible nanoparticles functionalized tumor-specific ligands. These serve as radiosensitizers, selectively increasing local radiation dose within microenvironment while minimizing exposure normal tissues. This delivery mechanism leverages precision nanotechnology enhance index. Results: Preclinical studies have shown NERT significantly improves outcomes cancer. The method achieves 97.4% efficiency, 45.2% 96.3% enhancement patient outcomes, 40.3% decrease systemic side-effects, 98.6% improvement targeting when radiotherapy. Conclusions: underscore transformative potential addressing key limitations treatments. By integrating advanced nanotechnology, enhances efficacy mitigating adverse effects, thereby improving outcomes. modality holds promise redefining clinical protocols elevating standards care oncology. proposed efficiency 97.4%, 45.2%, outcome 96.3%, systematic side-effect 40.3%, 98.6%.
Language: Английский